This is a recording of a previously presented live webinar. If you attended and received credit for the live webinar, you cannot get credit for this course. In this recorded webinar, you ll hear panelists discuss which diabetes meds may have cardiovascular (CV) benefits. We ll also review the evidence and discuss the pros and cons of SGLT2 inhibitors (empagliflozin, etc) and GLP-1 agonists (dulaglutide, etc) in patients with or at risk for CV disease (heart attack, stroke, heart failure, etc).
- Provider:TRC Healthcare-NetCE
- Activity Link: https://trchealthcare.com/login
- Start Date: 2025-03-01 06:00:00
- End Date: 2025-03-01 06:00:00
- Credit Details: IPCE Credits: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Yes
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest